Insider Buying: Opko Health Inc. (OPK) CEO Buys 185,000 Shares of Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 185,000 shares of the stock in a transaction on Friday, February 9th. The stock was bought at an average price of $3.83 per share, with a total value of $708,550.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $11,754,082.33. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, February 7th, Phillip Md Et Al Frost acquired 78,000 shares of Opko Health stock. The stock was bought at an average price of $4.22 per share, with a total value of $329,160.00.
  • On Monday, February 5th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average price of $4.14 per share, with a total value of $207,000.00.
  • On Friday, February 2nd, Phillip Md Et Al Frost acquired 55,000 shares of Opko Health stock. The stock was bought at an average price of $4.30 per share, with a total value of $236,500.00.
  • On Wednesday, January 31st, Phillip Md Et Al Frost acquired 65,000 shares of Opko Health stock. The stock was bought at an average price of $4.47 per share, with a total value of $290,550.00.
  • On Friday, January 26th, Phillip Md Et Al Frost acquired 55,000 shares of Opko Health stock. The stock was bought at an average price of $4.90 per share, with a total value of $269,500.00.
  • On Wednesday, January 24th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The stock was bought at an average price of $4.89 per share, with a total value of $489,000.00.
  • On Monday, January 22nd, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The stock was bought at an average price of $4.40 per share, with a total value of $440,000.00.

Shares of Opko Health Inc. (NASDAQ OPK) opened at $3.93 on Thursday. Opko Health Inc. has a 1 year low of $3.61 and a 1 year high of $8.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66. The company has a market cap of $2,200.00, a P/E ratio of -20.68 and a beta of 1.42.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Opko Health by 1.1% during the 2nd quarter. Vanguard Group Inc. now owns 26,618,758 shares of the biotechnology company’s stock worth $175,151,000 after buying an additional 296,757 shares during the period. State Street Corp grew its position in shares of Opko Health by 3.9% during the 2nd quarter. State Street Corp now owns 11,348,763 shares of the biotechnology company’s stock worth $74,671,000 after buying an additional 422,203 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Opko Health by 127.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock worth $27,466,000 after buying an additional 2,241,103 shares during the period. Geode Capital Management LLC grew its position in shares of Opko Health by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 3,429,271 shares of the biotechnology company’s stock worth $16,803,000 after buying an additional 78,477 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Opko Health by 83.7% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,579,950 shares of the biotechnology company’s stock worth $17,698,000 after buying an additional 1,175,726 shares during the period. Institutional investors own 22.68% of the company’s stock.

Several equities research analysts have weighed in on OPK shares. Cantor Fitzgerald set a $20.00 price objective on shares of Opko Health and gave the company a “buy” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Finally, BidaskClub cut shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $13.34.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.themarketsdaily.com/2018/02/15/insider-buying-opko-health-inc-opk-ceo-buys-185000-shares-of-stock.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply